Recently News

Predicting cancer therapy success

Author
Master
Date
2014-12-04 08:03
Views
34074

Nature - Cancer Immunology News
Source : Nature Magazine 2014,Dec

Predicting cancer therapy success



Tumour-cell genomes may hold clues to who will benefit from treatments that stimulate the immune system against melanoma.
A protein called CTLA-4 on the surface of cancer fighting T cells can suppress these immune cells’ attacks on the tumours. Drugs that block this protein can, in some patients, unleash these cells, but can have toxic side effects. Jedd Wolchok and Timothy Chan of the Memorial Sloan Kettering
Cancer Center in New York and their colleagues sequenced genes in tumour cells from 64 patients with melanoma who were treated with CTLA-4 inhibitors.
Patients whose tumours had a higher number of cancer-associated mutations were more likely to benefit from the drugs, and a set of 101 tumour proteins created by these mutations were associated with a strong response to the drugs.

N. Engl. J. Med. (2014)



.